12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Company News  |  Deals

CytoDyn, Progenics deal

CytoDyn completed its acquisition of Progenics' PRO 140 and related assets to treat HIV/AIDS infection for $3.5 million in cash. Progenics is...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >